Evidence map›Paper›PMID 28876532›Full record

ArticleThoracic cancer2017

Successful treatment with doxorubicin and ifosfamide for mediastinal malignant peripheral nerve sheath tumor with loss of H3K27me3 expression.

Noriko Seno, Toshirou Fukushima, Daisuke Gomi, Takashi Kobayashi, Nodoka Sekiguchi, Hidehiro Matsushita, Takesumi Ozawa, Yoshiko Tsukahara, Keiko Mamiya, Tomonobu Koizumi and 1 more

Abstract readCase Reports
In one paragraph

Article in Thoracic cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Noriko SenoDepartment of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Japan.
Toshirou FukushimaDepartment of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Japan.
Daisuke GomiDepartment of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Japan.
Takashi KobayashiDepartment of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Japan.
Nodoka SekiguchiDepartment of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Japan.
Hidehiro MatsushitaDepartment of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Japan.
Takesumi OzawaDepartment of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Japan.
Yoshiko TsukaharaDepartment of Anesthesiology and Resuscitology, Shinshu University School of Medicine, Matsumoto, Japan.
Keiko MamiyaDepartment of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Japan.
Tomonobu KoizumiDepartment of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Japan.ORCID 0000-0002-5182-0960
Kenji SanoDepartment of Laboratory Medicine, Shinshu University School of Medicine, Matsumoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant peripheral nerve sheath tumor (MPNST) in the thorax is an extremely rare disease, and half of all cases of MPNST are associated with neurofibromatosis type I. Sporadic intrathoracic MPNST is difficult to diagnose and treat. Because of the rarity of intrathoracic MPNST, the optimal method of diagnosis and the efficacy of chemotherapy are unknown. Herein, we present a case of inoperable mediastinal MPNST, in which the diagnosis was immunohistochemically made by the loss of H3K27me3 expression in a transbronchial needle biopsy specimen. The patient showed a good response to doxorubicin plus ifosfamide chemotherapy. The present case highlights that MPNST should be included in the differential diagnosis of non-posterior mediastinum thoracic lesions, and that appropriate diagnosis and treatment for intrathoracic MPNST should be considered in patients with a thoracic mass.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsDown-RegulationDoxorubicinFemaleGene Expression Regulation, NeoplasticHistonesHumansIfosfamideMediastinal NeoplasmsMiddle AgedNeurilemmomaTreatment OutcomeDoxorubicinHistonesIfosfamideChemotherapydoxorubicinifosfamidemediastinal tumor

Identifiers

PMID28876532
PMCPMC5668470

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.